share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
美股sec公告 ·  07/03 16:51
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. has announced the completion of a reverse stock split following approval from its stockholders at a special meeting held on May 28, 2024. The approved amendment to the company's Amended and Restated Certificate of Incorporation allows for a reverse stock split of its common stock at a ratio between 1-for-10 and 1-for-45, as determined by the Board of Directors. Concurrently, the sole outstanding share of Series A Preferred Stock was automatically redeemed. On June 28, 2024, Panbela Therapeutics filed a Certificate of Elimination with the Delaware Secretary of State, effectively eliminating all matters set forth in the Certificate of Designation of Series A Preferred Stock from April 23, 2024. This filing was made as part of the company's Current Report on Form 8-K, with the Certificate of Elimination included as Exhibit 3.1.
Panbela Therapeutics, Inc. has announced the completion of a reverse stock split following approval from its stockholders at a special meeting held on May 28, 2024. The approved amendment to the company's Amended and Restated Certificate of Incorporation allows for a reverse stock split of its common stock at a ratio between 1-for-10 and 1-for-45, as determined by the Board of Directors. Concurrently, the sole outstanding share of Series A Preferred Stock was automatically redeemed. On June 28, 2024, Panbela Therapeutics filed a Certificate of Elimination with the Delaware Secretary of State, effectively eliminating all matters set forth in the Certificate of Designation of Series A Preferred Stock from April 23, 2024. This filing was made as part of the company's Current Report on Form 8-K, with the Certificate of Elimination included as Exhibit 3.1.
Panbela Therapeutics公司已宣佈完成股票拆分，經股東於2024年5月28日的特別會議批准。公司修正的章程覈准了普通股的股票拆分比率在1股至10股和1股至45股之間，具體比率由董事會決定。同時，A系列優先股唯一的一股已自動贖回。2024年6月28日，Panbela Therapeutics向特拉華州州務卿提交了一份“清除證書”，有效地消除了自2024年4月23日A系列優先股的指定證書中規定的所有事項。此文件是公司“8-K表格”的一部分，其中包括了“清除證書”作爲展示文件3.1。
Panbela Therapeutics公司已宣佈完成股票拆分，經股東於2024年5月28日的特別會議批准。公司修正的章程覈准了普通股的股票拆分比率在1股至10股和1股至45股之間，具體比率由董事會決定。同時，A系列優先股唯一的一股已自動贖回。2024年6月28日，Panbela Therapeutics向特拉華州州務卿提交了一份“清除證書”，有效地消除了自2024年4月23日A系列優先股的指定證書中規定的所有事項。此文件是公司“8-K表格”的一部分，其中包括了“清除證書”作爲展示文件3.1。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息